A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

Khanna, D., Denton, C.P., Assassi, S. et al. (12 more authors) (2024) A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale. Clinical and Experimental Rheumatology, 42 (8). pp. 1635-1644. ISSN 0392-856X

Abstract

Metadata

Item Type: Article
Authors/Creators:
  • Khanna, D.
  • Denton, C.P.
  • Assassi, S.
  • Kuwana, M.
  • Allanore, Y.
  • Domsic, R.T.
  • Kleoudis, C.
  • Xu, J.
  • Csomor, E.
  • Seo, C.
  • Albulescu, M.
  • Tummala, R.
  • Al-Mossawi, H.
  • Kalyani, R.N.
  • Del Galdo, F. ORCID logo https://orcid.org/0000-0002-8528-2283
Keywords: autoimmune disease, systemic sclerosis, anifrolumab, type I interferon
Dates:
  • Published: 14 August 2024
  • Published (online): 14 August 2024
  • Accepted: 10 June 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 02 Dec 2024 14:03
Last Modified: 02 Dec 2024 14:05
Published Version: https://www.clinexprheumatol.org/abstract.asp?a=21...
Status: Published
Publisher: Clinical and Experimental Rheumatology
Identification Number: 10.55563/clinexprheumatol/s8qcyu
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics